, Volume 43, Issue 4, pp 403–405 | Cite as

Development of high blood pressure in spontaneously hypertensive rats is delayed by treatment with cyclosporin at an early age

  • J. M. A. Sitsen
  • W. de Jong
Short Communications


In spontaneously hypertensive rats the effect of the T-cell inhibitor cyclosporin was studied at different ages. If treatment was started at the age of 2 weeks the development of hypertension was delayed, but the ultimate level of blood pressure was not affected. These results indicate the involvement of immune mechanisms in the early development of hypertension in spontaneously hypertensive rats.

Key words

SHR cyclosporin immune mechanisms hypertension 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Okamoto, K., and Aoki, K., Jap. Circ. J.27, (1963) 282.PubMedGoogle Scholar
  2. 2.
    Takeichi, N., and Boone, Ch.W., Cell Immun.27 (1976) 52.CrossRefGoogle Scholar
  3. 3.
    Takeichi, N., Suzuki, K., Okayasu, T., and Kobayashi, H., Clin. expl Immun.40 (1980) 120.Google Scholar
  4. 4.
    Takeichi, N., Ba, D., and Kobayashi, H., Cell. Immun.60 (1981) 181.CrossRefGoogle Scholar
  5. 5.
    Takeichi, N., Suzuki, K., and Kobayashi, H., Eur. J. Immun.11 (1981) 483.Google Scholar
  6. 6.
    Ba, D., Takeichi, N., Kodama, T., and Kobayashi, H., J. Immun.128 (1982) 1211.PubMedGoogle Scholar
  7. 7.
    Strausser, H.R., Thymus5 (1983) 19.PubMedGoogle Scholar
  8. 8.
    Bendich, A., Belisle, E.H., and Strausser, H.R., Biochem. biophys. Res. Commun.99 (1981) 600.CrossRefPubMedGoogle Scholar
  9. 9.
    Norman, R.A., Dzielak, D.J., Bost, K.L., Cuchens, M.A., and Khraibi, A.A., Physiologist26 (1983) A-48 (Abstr. 26.9).Google Scholar
  10. 10.
    Norman, R.A., Dzielak, D.J., Bost, K.L., Khraibi, A.A., and Galloway, P.G., J. Hypertension3 (1985) 261.Google Scholar
  11. 11.
    Khraibi, A.A., Norman, R.A., and Dzielak, D.J., Physiologist25 (1982) 337 (Abstr. 70.7).Google Scholar
  12. 12.
    Khraibi, A.A., Norman, R.A., and Dzielak, D.J., Am. J. Physiol.247 (1984) H722.PubMedGoogle Scholar
  13. 13.
    Borel, J.F., Rüegger, A., and Stähelin, H., Experientia32 (1976) 777.Google Scholar
  14. 14.
    Britton, S. and Palacios, R., Immun. Rev.65 (1982) 5.PubMedGoogle Scholar
  15. 15.
    Wagner, H., Trans. Proc.15, (1983) 523.Google Scholar
  16. 16.
    Leenen, F.H., and Jong, W. de, J. appl. Physiol.31 (1971) 142.PubMedGoogle Scholar
  17. 17.
    Borel, J. F., Feurer, C., Grubler, H.V., and Stähelin, H., Agent Action6 (1976) 468.Google Scholar
  18. 18.
    Borel, J.F., Feurer, C., and Magnée, C., Immunology32 (1977) 1017.PubMedGoogle Scholar
  19. 19.
    Okuda, T., and Grollman, A., Tex. Rep. Biol. Med.25 (1967) 257.PubMedGoogle Scholar
  20. 20.
    Provoost, A.P., and Keyzer, M.H. de, in: Handbook of Hypertension, vol. 4: Experimental and genetic models of hypertension, p. 518. Ed. W. de Jong. Elsevier Science Publishers, Amsterdam 1985.Google Scholar
  21. 21.
    Kristensen, B.Ø., J. Hypertension2 (1978) 571.Google Scholar
  22. 22.
    Gualde, N., Michel, J.P., and Safar, M.E., Lancet2 (1978) 897.CrossRefGoogle Scholar
  23. 23.
    Löw, B., Schersten, B., Sanetor, G., Thulin, T., and Mitelman, F., Lancet2 (1975) 695.CrossRefPubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1987

Authors and Affiliations

  • J. M. A. Sitsen
    • 1
  • W. de Jong
    • 1
  1. 1.Rudolf Magnus Institute for Pharmacology, Medical FacultyState University of UtrechtUtrecht(The Netherlands)

Personalised recommendations